Introduction
============

Colorectal cancer is the third most common type of cancer for both males and females. In 2010, there were an estimated 102,900 new cases of colon and 39,670 cases of rectal cancer, and an estimated 51,370 deaths from colorectal cancer occurred.[@b1-cin-11-2012-001],[@b2-cin-11-2012-001] The five-year survival rate for those patients who are diagnosed at an early stage (localized stage---stage I or II) is 91%; however, only 39% of colorectal cancer patients are diagnosed at an early stage.[@b1-cin-11-2012-001] If the colorectal cancer has spread to adjacent organs or lymph nodes, the five-year survival drops to 70%, and if it has spread to distant organs, the five-year survival is 11%.[@b1-cin-11-2012-001] It follows, therefore, that early and accurate diagnostic tests would have a significant impact in the fight against this disease by saving thousands of lives every year. Furthermore, if an early and accurate diagnostic test were based on serum or blood, then it would have additional significant advantages: it would be considerably less invasive and expensive than colonoscopy, the current standard diagnostic procedure for colon cancer (CCA).

In this study, we analyzed the global micro-RNA (miRNA) expression data of colonic tumor and healthy tissue obtained during surgery from 96 subjects \[68 with CCA (stages II--IV) and 28 normal\]. We developed three different and independent diagnostic biomarker models using 57 subjects \[40 with CCA (stages II--IV) and 17 normal\], and we validated all three of them with 39 unknown subjects \[28 with CCA (stages II--IV) and 11 normal\] that were new and different from those 57 subjects used in the development of the models. Our three diagnostic biomarker models were able to identify with a perfect accuracy (overall sensitivity: 100.00% and overall specificity: 100.00%) all 68 subjects with CCA and all 28 normal subjects.

Each of our three diagnostic biomarker models is a linear discriminant function of a number of miRNAs. Altogether, nine miRNAs constitute the input variables to all three diagnostic biomarker models, and they are deemed highly significant in the discrimination between healthy normal tissue and tumor tissue, as well as, therefore, in the development of colon cancer.

Materials and Methods
=====================

Data acquisition
----------------

We used the normalized miRNA data for 68 subjects with CCA (stages II--IV) (labeled 'pMMR') and for 28 normal subjects by Sarver et al[@b3-cin-11-2012-001] posted at the GEO (Gene Expression Omnibus) of the NCBI (National Center for Biotechnology Information) \[ID: GSE18392\].

Discovery and validation studies
--------------------------------

Of the total 96 subjects, we randomly selected 57 of them \[40 with CCA (stages II--IV) and 17 normal (NRM)\] for the development and training of the diagnostic biomarker models. The remaining 39 subjects \[28 with CCA (stages II--IV) and 11 NRM\] constituted the unknown subjects with which all diagnostic biomarker models were tested. This validation method provided us with the means to test our diagnostic biomarker models with 39 new and real unknowns that were different from the subjects used for---and, therefore, completely extraneous to---the development and training of the models. The proportions of the stages (II--IV) in the total set of 68 CCA subjects were maintained in both the discovery and validation subsets of CCA subjects.

Statistical methods
-------------------

In order to reduce the dimensionality of the data and zero in on those variables (miRNAs) that are most significant in the process that differentiates between normal healthy tissue and CCA tissue, we applied our bioinformatic methods that we have developed, presented, and explained in a great detail in our previous studies.[@b4-cin-11-2012-001]--[@b7-cin-11-2012-001] Briefly, we performed ROC curve analysis on the entire data matrix, i.e., on all variables (735 miRNAs × 96 subjects) in order to assess the discriminating capability of all variables with respect to our two groups, namely, CCA and NRM. In the final round, we selected only those variables with an AUC ≥ 0.97. Twelve variables (miRNAs) fulfilled this criterion, and they constituted the final pool of the most significant variables. We should point out that our method used in this study constitutes a novel linear discriminant analysis method, i.e., one that is carefully supervised by ROC curve analysis.

### Generation of linear discriminant functions

From the aforementioned 12 most significant variables, 9 became the input variables to the three linear discriminant functions (D~1~, D~2~, and D~3~), which we were able to generate in the discovery study {57 subjects \[40 with CCA (stages II--IV) and 17 NRM\]}. Those three different and independent linear discriminant functions are the final diagnostic biomarker models. The D~1~ is a function of the following 4 of the 9 aforementioned significant variables (miRNAs):
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The letter 'T' preceding the name of a miRNA indicates that that miRNA variable was transformed in order to meet normality, equality of variance, and/or equality of covariance requirements.

The D~2~ is a function of the following 3 of the 9 aforementioned significant variables (mi RNAs):
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The D~3~ is a function of the following 4 of the 9 aforementioned significant variables (miRNAs):
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As can be seen from [Equations (1.1)](#FD1){ref-type="disp-formula"}, [(1.2)](#FD2){ref-type="disp-formula"}, and [(1.3)](#FD3){ref-type="disp-formula"}, the three linear discriminant functions D~1~, D~2~, and D~3~ are three different and independent functions. [Table S1 (Supplementary Data)](#s1-cin-11-2012-001){ref-type="supplementary-material"} shows the exact D~1~, D~2~, and D~3~ functions. [Table 1](#t1-cin-11-2012-001){ref-type="table"} shows the top 12 most significant miRNAs, including the 9 miRNAs that constitute the input variables to D~1~, D~2~, and D~3~ functions, along with their ROC AUC rank, relative expression, and other properties.

As was mentioned above, 9 of the 12 most significant miRNA variables were employed to develop the D~1~, D~2~, and D~3~ functions. The remaining 3 miRNA variables were not employed due to high degree of multi collinearity, as well as due to inequality of covariance, with the other miRNA variables. For those same reasons, the D~1~, D~2~, and D~3~ functions with their respective miRNA variables represent the miRNA groups (out of the 12 most significant miRNA variables) that fulfilled all conditions required by discriminant analysis. [Table S2 ( Supplementary Data)](#s2-cin-11-2012-001){ref-type="supplementary-material"} shows the test results for equality of covariance and variance among the constituent miRNA variables of the D~1~, D~2~, and D~3~ functions. [Table S3 ( Supplementary Data)](#s3-cin-11-2012-001){ref-type="supplementary-material"} shows the test results for normality for the D~1~, D~2~, and D~3~ functions. We should point out here that, having lowered the criterion of significance (ROC AUC ≥ 0.90), we were able to generate several other discriminant functions, whose constituent miRNA variables were less significant than those employed by the D~1~, D~2~, and D~3~ functions; but, following final assessment, they proved to be not as robust as the D~1~, D~2~, and D~3~, and they are consequently not presented here.

The D~1~, D~2~, and D~3~ functions that we generated are canonical linear discriminant functions; this means that all three of them, by definition, are centered at zero, i.e., the mean D~1~, D~2~, and D~3~ scores of the 57 subjects used in the discovery study are all zero. In order to avoid having to deal with negative scores, especially in the case of the graphs, we centered all three discriminant functions at +20.

Computer programs
-----------------

Computer programs were written using MATLAB R2011b by The MathWorks, Inc., Natick, MA, USA.

Results
=======

Discovery study
---------------

As was mentioned earlier, from the total number of 96 subjects \[68 with CCA (stages II--IV) and 28 NRM\] used in this study, we randomly selected 57 subjects \[40 with CCA (stages II--IV) and 17 NRM\] for the development and training of the three diagnostic biomarker models (D~1~, D~2~, and D~3~); and we will henceforward refer to those 57 subjects as the 57 original subjects. After the development of the three diagnostic biomarker models, we assessed their diagnostic accuracy using the aforementioned 57 original subjects, which were employed for their development. This constitutes an important first step in the assessment of a diagnostic test.

The cut-off score of the D~1~ diagnostic biomarker model, as well as those of the other two models, was determined by taking into account the results of the following two analyses: (1) calculation of the optimal point on the ROC curve based on the 57 scores of the 57 original subjects used in the discovery study \[ optimal point is defined as the point with the highest sensitivity and the lowest false positive rate ( 1-specificity)\] and (2) calculation of the 99.99% confidence intervals for the mean D~1~ scores of the two groups (CCA and NRM) and their respective standard deviations. Based on that, the cut-off score of the D~1~ model was determined to be 21.800. If a subject has a D~1~ score less than 21.800, then that subject is classified as a CCA; otherwise (≥21.800), that subject is classified as an NRM. As can be seen from [Figure 1](#f1-cin-11-2012-001){ref-type="fig"}, the D~1~ model correctly identified all (40/40) CCA subjects and all (17/17) NRM subjects. Since our target group is the CCA group, and since our reference group is the NRM group, it follows that, for the discovery study, the D~1~ model exhibited a sensitivity = 40/40 = 1.000 and a specificity = 17/17 = 1.000. [Figure 1](#f1-cin-11-2012-001){ref-type="fig"} and [Table 2A](#t2-cin-11-2012-001){ref-type="table"} show all pertinent statistical results of the D~1~ diagnostic biomarker model in connection with the discovery study in great detail.

The cut-off score of the D~2~ diagnostic biomarker model was determined to be 21.235. If a subject has a D~2~ score less than 21.235, then that subject is classified as a CCA; otherwise (≥21.235), that subject is classified as an NRM. As can be seen from [Figure 1](#f1-cin-11-2012-001){ref-type="fig"}, the D~2~ model correctly identified all (40/40) CCA subjects and all (17/17) NRM subjects. Therefore, for the discovery study, the D~2~ model exhibited a sensitivity = 40/40 = 1.000 and a specificity = 17/17 = 1.000. [Figure 1](#f1-cin-11-2012-001){ref-type="fig"} and [Table 2A](#t2-cin-11-2012-001){ref-type="table"} show all pertinent statistical results of the D~2~ diagnostic biomarker model in connection with the discovery study in great detail.

Regarding the D~3~ diagnostic biomarker model, the cut-off score was determined to be 21.382. If a subject has a D~3~ score less than 21.382, then that subject is classified as a CCA; otherwise (≥21.382), that subject is classified as an NRM. As can be seen from [Figure 2](#f2-cin-11-2012-001){ref-type="fig"}, the D~3~ model correctly identified all (40/40) CCA subjects and all (17/17) NRM subjects. Therefore, for the discovery study, the D~3~ model exhibited a sensitivity = 40/40 = 1.000 and a specificity = 17/17 = 1.000. [Figure 2](#f2-cin-11-2012-001){ref-type="fig"} and [Table 2A](#t2-cin-11-2012-001){ref-type="table"} show all pertinent statistical results of the D~3~ diagnostic biomarker model in connection with the discovery study in great detail.

[Figure 3](#f3-cin-11-2012-001){ref-type="fig"} shows the 3D scatter plot of the D~1~ vs. D~2~ vs. D~3~ scores of all 57 original subjects, providing, thus, a visual depiction of the diagnostic accuracy of all three models with respect to the discovery study. As can be seen, the two groups are segregated into two distinct and completely separate clusters: the CCA group (purple spheres) is at the front and lower level, whereas the NRM group (green spheres) is at the back and higher level. It can also be seen that there were no misclassifications by any of the three diagnostic models.

Validation study
----------------

As was mentioned earlier, from the total number of 96 subjects \[68 with CCA (stages II--IV) and 28 NRM\] used in this study, we had randomly segregated 39 subjects \[28 with CCA (stages II--IV) and 11 NRM\] for the sole and express purpose of testing our three diagnostic biomarker models. Those 39 unknown subjects were completely extraneous to all three models, that is to say they were new and different from the original 57 subjects used for the development of the three models, and they had never before been encountered by any of the three models. This constitutes the most important test in the assessment of a diagnostic test.

As can be seen from [Figures 4](#f4-cin-11-2012-001){ref-type="fig"} and [5](#f5-cin-11-2012-001){ref-type="fig"} and [Table 2B](#t2-cin-11-2012-001){ref-type="table"}, all three diagnostic biomarker models correctly diagnosed all of the 39 unknown subjects. More specifically, all 28 unknown CCA subjects had D~1~, D~2~, and D~3~ scores that were less than the respective cut-off scores (21.800, 21.235, 21.382); whereas all 11 unknown NRM subjects had D~1~, D~2~, and D~3~ scores that were greater than the respective aforementioned cut-off scores. Therefore, in connection with the validation study, both the sensitivity and the specificity of all three diagnostic biomarker models were 1.000. [Figure 6](#f6-cin-11-2012-001){ref-type="fig"} shows the 3D scatter plot of the D~1~ vs. D~2~ vs. D~3~ scores of all 39 unknown subjects, providing, thus, a visual depiction of the diagnostic accuracy of all three models with respect to the validation study. As can be seen, the 39 unknown subjects are segregated into two distinct and completely separate clusters: the CCA group (purple spheres) is at the front and lower level, whereas the NRM group (green spheres) is at the back and higher level. It can also be seen that there were no misclassifications by any of the three diagnostic models.

[Table 2B](#t2-cin-11-2012-001){ref-type="table"}, in addition to other pertinent statistical results of our three diagnostic biomarker models, shows the observed mean D~1~, D~2~, and D~3~ scores of the two groups (CCA and NRM) of the 39 unknown subjects. As can be seen, all six of those group mean scores, as observed in the validation study with the 39 unknown subjects, fall within the 99.99% confidence intervals of the respective group mean scores as predicted in the discovery study ([Table 2A](#t2-cin-11-2012-001){ref-type="table"}).

Overall diagnostic biomarker model performance
----------------------------------------------

If we combined the discovery study results with those of the validation study, then the overall performance of our three diagnostic biomarker models would be as follows. All three of them (D~1~, D~2~, and D~3~) exhibited an overall sensitivity = 1.000 (68/68 CCA subjects) and an overall specificity = 1.000 (28/28 NRM subjects).

On the top 12 most significant miRNAs
-------------------------------------

In connection with the aforementioned 12 most significant miRNAs identified in our study, we conducted an Ingenuity Pathway Analysis (IPA) search. We sought to ascertain information about those 12 miRNAs pertaining to their known interactions with genes; their known interactions with drugs, chemicals, and/or hormones; and their known associations with various types of cancer as derived from the findings of scientific, peer-reviewed studies. The IPA search results are listed in [Table 1](#t1-cin-11-2012-001){ref-type="table"}, along with the direction of the statistically significant differential expression (over-expression or under-expression) of those 12 miRNAs in the CCA group relative to that of the NRM group. As can be seen from [Table 1](#t1-cin-11-2012-001){ref-type="table"}, nearly all of those 12 miRNAs are known to interact with genes, such as RASA1, TP53, CDK6, BCL10, EGR1, and RB1---genes that are involved in the regulation of oncogenesis.

Numerous miRNAs have been observed to be differentially expressed in various types of cancer as compared with the normal healthy state. More specifically, miR-183 and miR-135b have been observed to be over-expressed in colon cancer cells as compared to healthy tissue cells,[@b8-cin-11-2012-001],[@b9-cin-11-2012-001] and that agrees with our results ([Table 1](#t1-cin-11-2012-001){ref-type="table"}). Also in connection with colon cancer, miR-182\* and miR-224 have been observed to be over-expressed, whereas miR-30a- 3p and miR- 137 have been observed to be under-expressed;[@b8-cin-11-2012-001] those observations are also in agreement with our findings ([Table 1](#t1-cin-11-2012-001){ref-type="table"}). In connection with colon cancer cell lines, miR-182 and miR-147 have been observed to be over-expressed and under-expressed, respectively;[@b8-cin-11-2012-001] and that also accords with the results of our analysis ([Table 1](#t1-cin-11-2012-001){ref-type="table"}). In the cases of hypopharyngeal squamous cell carcinoma and gastric cancer, miR-378 has been observed to be under-expressed,[@b9-cin-11-2012-001],[@b10-cin-11-2012-001] which is in agreement with our findings. In the cases of prostate cancer and lung cancer, miR-30a-5p has been observed to be under-expressed,[@b11-cin-11-2012-001],[@b12-cin-11-2012-001] and that is also in agreement with our findings.

The original study by Sarver et al[@b3-cin-11-2012-001] was an observational study. Using the criteria of *P* value and fold change, the authors reported over forty miRNAs that were determined to be differentially expressed between the subjects with colon cancer and the normal subjects. We should point out here that Sarver et al[@b3-cin-11-2012-001] did not develop any diagnostic models (tests), much less validate them with unknown subjects that were new and different from the original subjects and report the performance results of such diagnostic models (tests).

Discussion
==========

Having employed 57 subjects \[40 with CCA (stages II--IV) and 17 NRM\], we were able to generate three different and independent linear discriminant functions, i.e. three different and independent diagnostic tests, that, based on the global miRNA analysis of tissue, can diagnose with perfect accuracy colon cancer. Following validation with 39 unknown (new and different) subjects \[28 with CCA (stages II--IV) and 11 NRM\], our three diagnostic tests (D~1~, D~2~, and D~3~) exhibited an overall sensitivity = 1.000 (68/68 CCA subjects) and an overall specificity = 1.000 (28/28 NRM subjects). This robust performance should be further tested using a wider pool of subjects in terms of demographics, family history, and syndromic associations.

The clinical significance of our study is as follows. We were able to develop and independently validate three different and independent diagnostic tests that, based on the global miRNA analysis of tumor and healthy tissue, can discriminate with a perfect accuracy between subjects with colon cancer and normal subjects. The nine most significant miRNAs identified, which comprise the input variables to our three diagnostic tests, play, therefore, a key role in the development of colon cancer, as evidenced by the tissue analysis. If an accurate and reliable detection and quantification of those nine key miRNAs were possible in the circulation (plasma or serum), then that would lead to early, accurate, and far less invasive diagnostic tests for colon cancer. Since early detection of colon cancer is associated with 91% survival,[@b1-cin-11-2012-001] the results of our study may have a significant impact in the fight against this disease by contributing to the saving of thousands of lives of patients with colon cancer each year.

Detection of miRNAs in the circulation, be it in circulating tumor cells[@b13-cin-11-2012-001] or in exosomes,[@b14-cin-11-2012-001],[@b15-cin-11-2012-001] has been demonstrated by numerous studies over the last several years. Circulating miRNAs have also been detected in connection with various types of cancer, such as breast cancer,[@b15-cin-11-2012-001] prostate cancer,[@b16-cin-11-2012-001] liver cancer,[@b17-cin-11-2012-001] esophageal cancer,[@b18-cin-11-2012-001] etc. Therefore, identifying and quantifying accurately and reliably, either in serum or in plasma, the aforementioned nine miRNAs that play a key role in the development of colon cancer constitutes the ultimate goal of this study.
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Supplementary Tables
====================

###### 

Canonical linear discriminant functions of D~1~, D~2~, and D~3~ diagnostic biomarker models developed from the original 57 subjects \[17 NRM (Group 0) and 40 CCA (Group 1)\].

  Discriminant Analysis Report             
  ------------------------------ ---- ---- ---------
  Group                          0    1    Overall
  Count                          17   40   57

  Variable                            Canonical Variate
  ----------------------------------- -------------------
  **Canonical coefficients (D~1~)**   
  Constant                            −18.363945
  miR_182                             −0.146842
  miR_30a_5p                          1.612585
  miR_183                             −0.609552
  TmiR_378                            0.000264
  **Canonical coefficients (D~2~)**   
  Constant                            −0.360000
  miR_182\*                           −1.018370
  miR_147                             0.800789
  TmiR_30a_3p                         0.0000002
  **Canonical coefficients (D~3~)**   
  Constant                            −16.476653
  miR_182                             −1.216682
  miR_137                             0.566376
  TmiR_30a_3p                         0.169121
  TmiR_224                            271.728594

**Notes:** The constituent miRNA variables, their respective coefficients, and the constant of each of the three canonical linear discriminant functions (D~1~, D~2~, and D~3~) are shown. The letter 'T' preceding the name of a miRNA indicates that that miRNA variable was transformed in order to meet normality, equality of variance, and/or equality of covariance requirements.

###### 

Test results for equality of covariance and variance among the constituent miRNA variables of the D~1~, D~2~, and D~3~ functions developed from the original 57 subjects \[17 NRM (Group 0) and 40 CCA (Group 1)\].

  Equality of Covariance and Variance Report             
  -------------------------------------------- ---- ---- ---------
  Group                                        0    1    Overall
  Count                                        17   40   57

  Variable                                    Barlett   F    F      Chi2   Chi2               
  ------------------------------------------- --------- ---- ------ ------ ---------- ------- ----------
  **Bartlett-Box homogeneity tests (D~1~)**                                                   
  miR_182                                     0.8189    1    5517   0.80   0.371063   0.80    0.371148
  miR_30a_5p                                  2.3170    1    5517   2.26   0.132402   2.26    0.132496
  miR_183                                     0.2023    1    5517   0.20   0.656596   0.20    0.656644
  TmiR_378                                    2.1038    1    5517   2.06   0.151640   2.05    0.151736
  Box's M                                     8.6511    10   4538   0.78   0.651808   7.78    0.649968
  **Bartlett-Box homogeneity tests (D~2~)**                                                   
  miR_182\*                                   2.2110    1    5517   2.16   0.141599   2.16    0.141693
  miR_147                                     0.1519    1    5517   0.15   0.700072   0.15    0.700114
  TmiR_30a_3p                                 0.0523    1    5517   0.05   0.821247   0.05    0.821272
  Box's M                                     6.6653    6    6101   1.03   0.406328   6.16    0.405495
  **Bartlett-Box homogeneity tests (D~3~)**                                                   
  miR_182\*                                   0.8189    1    5517   0.80   0.371063   0.80    0.371148
  miR_137                                     0.0281    1    5517   0.03   0.868393   0.03    0.868412
  TmiR_30a_3p                                 0.0523    1    5517   0.05   0.821247   0.05    0.821272
  TmiR_224                                    2.3096    1    5517   2.26   0.133022   2.26    0.133116
  Box's M                                     14.9302   10   4538   1.34   0.202563   13.43   0.200457

**Notes:** As can be seen from the probability of significance values of both the F and the χ^2^ tests for the Box's M test, there are no statistically significant covariance differences among the constituent miRNA variables of the D~1~, D~2~, or D~3~ function. Likewise, the Bartlett test shows that there are no statistically significant variance differences among the constituent miRNA variables of the D~1~, D~2~, or D~3~ function.

###### 

Normality test results for the D~1~, D~2~, and D~3~ linear discriminant functions with respect to both groups of the original 57 subjects \[17 NRM (Group 0) and 40 CCA (Group 1)\] used for the development of the three functions.

  Normality Tests Report                                                                                                 
  ------------------------------------------------------------------ -------------- -------------- ---------- ---------- ------------------------
  **Normality test section of D~1~** **when Group = 0 (Count 17)**                                                       
  Shapiro-Wilk W                                                     0.9679477      0.7815679                            Can't reject normality
  Anderson-Darling                                                   0.3600979      0.4483844                            Can't reject normality
  Martinez-lglewicz                                                  1.135777                      1.252524   1.438767   Can't reject normality
  Kolmogorov-Smirnov                                                 0.1029178                     0.19       0.207      Can't reject normality
  D'Agostino Skewness                                                −0.6319371     0.527428       1.645      1.960      Can't reject normality
  D'Agostino Kurtosis                                                0.9578         0.338181       1.645      1.960      Can't reject normality
  D'Agostino Omnibus                                                 1.3167         0.517716       4.605      5.991      Can't reject normality
  **Normality test section of D~1~** **when Group = 1 (Count 40)**                                                       
  Shapiro-Wilk W                                                     0.9523966      9.170641E-02                         Can't reject normality
  Anderson-Darling                                                   0.4800356      0.233547                             Can't reject normality
  Martinez-lglewicz                                                  0.9609824                     1.114676   1.175041   Can't reject normality
  Kolmogorov-Smirnov                                                 0.0905983                     0.126      0.139      Can't reject normality
  D'Agostino Skewness                                                −0.3980126     0.6906209      1.645      1.960      Can't reject normality
  D'Agostino Kurtosis                                                −2.4009        0.016356       1.645      1.960      Reject normality
  D'Agostino Omnibus                                                 5.9226         0.051752       4.605      5.991      Can't reject normality
  **Normality test section of D~2~** **when Group = 0 (Count 17)**                                                       
  Shapiro-Wilk W                                                     0.9018213      7.286435E-02                         Can't reject normality
  Anderson-Darling                                                   0.6532255      8.824592E-02                         Can't reject normality
  Martinez-lglewicz                                                  1.067013                      1.252524   1.438767   Can't reject normality
  Kolmogorov-Smirnov                                                 0.1256069                     0.19       0.207      Can't reject normality
  D'Agostino Skewness                                                −1.408385      0.159017       1.645      1.960      Can't reject normality
  D'Agostino Kurtosis                                                −0.4372        0.661989       1.645      1.960      Can't reject normality
  D'Agostino Omnibus                                                 2.1747         0.337114       4.605      5.991      Can't reject normality
  **Normality test section of D~2~** **when Group = 1 (Count 40)**                                                       
  Shapiro-Wilk W                                                     0.9654804      0.2565536                            Can't reject normality
  Anderson-Darling                                                   0.4056016      0.3517282                            Can't reject normality
  Martinez-lglewicz                                                  1.038377                      1.114676   1.175041   Can't reject normality
  Kolmogorov-Smirnov                                                 7.907125E-02                  0.126      0.139      Can't reject normality
  D'Agostino Skewness                                                −1.585528      0.1128464      1.645      1.960      Can't reject normality
  D'Agostino Kurtosis                                                0.4021         0.687630       1.645      1.960      Can't reject normality
  D'Agostino Omnibus                                                 2.6756         0.262427       4.605      5.991      Can't reject normality
  **Normality test section of D~3~** **when Group = 0 (Count 17)**                                                       
  Shapiro-Wilk W                                                     0.9496766      0.4514251                            Can't reject normality
  Anderson-Darling                                                   0.3490809      0.4751235                            Can't reject normality
  Martinez-lglewicz                                                  1.136325                      1.252524   1.438767   Can't reject normality
  Kolmogorov-Smirnov                                                 0.1442362                     0.19       0.207      Can't reject normality
  D'Agostino Skewness                                                1.580456       0.1140025      1.645      1.960      Can't reject normality
  D'Agostino Kurtosis                                                1.5018         0.133142       1.645      1.960      Can't reject normality
  D'Agostino Omnibus                                                 4.7533         0.092860       4.605      5.991      Can't reject normality
  **Normality test section of D~3~** **when Group = 1 (Count 40)**                                                       
  Shapiro-Wilk W                                                     0.9784388      0.6317195                            Can't reject normality
  Anderson-Darling                                                   0.2572377      0.7206884                            Can't reject normality
  Martinez-lglewicz                                                  0.9622557                     1.114676   1.175041   Can't reject normality
  Kolmogorov-Smirnov                                                 7.959955E-02                  0.126      0.136      Can't reject normality
  D'Agostino Skewness                                                0.802801       0.4220898      1.645      1.960      Can't reject normality
  D'Agostino Kurtosis                                                −0.6426        0.520487       1.645      1.960      Can't reject normality
  D'Agostino Omnibus                                                 1.0574         0.589366       4.605      5.991      Can't reject normality

**Note:** As can be seen, D~1~, D~2~, and D~3~ are normally distributed with respect to both groups.

![Scatter plot and bar graph of all 57 original subjects (40 CCA and 17 NRM) used in the Discovery Study in connection with the D~1~ and D~2~ diagnostic biomarker models.\
**Notes:** As can be seen, 40/40 CCA subjects (purple color) had D~1~ and D~2~ scores lower than the determined cut-off scores of 21.800 and 21.235, respectively; therefore, 40/40 CCA subjects were identified correctly by both D~1~ and D~2~ diagnostic biomarker models \[sensitivity = 40/40 = 1.000 for both D~1~ and D~2~\]. Regarding the NRM group (green color), all 17 subjects had D~1~ and D~2~ scores greater than the determined cut-off scores of 21.800 and 21.235, respectively; therefore, 17/17 NRM subjects were identified correctly by both D~1~ and D~2~ diagnostic biomarker models \[specificity = 17/17 = 1.000 for both D~1~ and D~2~\]. For the Discovery Study, the mean D~1~ and D~2~ scores of the 40 CCA subjects were18.4054 and 18.3266 respectively (top of the D~1~ and D~2~ purple bars) and their respective standard deviations (whiskers above or below the top of the D~1~ and D~2~ purple bars) were 1.0899 and 1.0703. The mean D~1~ and D~2~ scores of the 17 NRM subjects were 23.7523 and 23.9373 respectively (top of the D~1~ and D~2~ green bars) and their respective standard deviations (whiskers above or below the top of the D~1~ and D~2~ green bars) were 0.7363 and 0.8029. The significance level was set at α = 0.001 (two-tailed), and the probability of significance for the D~1~ was *P* = 3.05 × 10^−25^ (independent *t*-Test with T-value = 18.4664), whereas the probability of significance for the D~2~ was *P* = 3.01 × 10^−26^ (independent *t*-Test with T-value = 19.3834). Both the D~1~ and the D~2~ are parametrically distributed with respect to both groups.](cin-11-2012-001f1){#f1-cin-11-2012-001}

![Scatter plot and bar graph of all 57 original subjects (40 CCA and 17 NRM) used in the Discovery Study in connection with the D~3~ diagnostic biomarker model.\
**Notes:** As can be seen, 40/40 CCA subjects (purple color) had D~3~ scores lower than the determined cut-off score of 21.382; therefore, 40/40 CCA subjects were identified correctly by the D~3~ diagnostic biomarker model \[sensitivity = 40/40 = 1.000\]. Regarding the NRM group (green color), all 17 subjects had D~3~ scores greater than the determined cut-off score of 21.382; therefore, 17/17 NRM subjects were identified correctly by the D~3~ diagnostic biomarker model \[specificity = 17/17 = 1.000\]. For the Discovery Study, the mean D~3~ score of the 40 CCA subjects was 18.0010 (top of the purple bar) and the standard deviation (whiskers above or below the top of the purple bar) was 0.9684. The mean D~3~ score of the 17 NRM subjects was 24.7016 (top of the green bar) and the standard deviation (whiskers above or below the top of the green bar) was 1.0730. The significance level was set at α = 0.001 (two-tailed), and the probability of significance for the D~3~ was *P* = 4.96 × 10^−30^ (independent *t*-Test with T-value = 23.1476). The D~3~ is parametrically distributed with respect to both groups.](cin-11-2012-001f2){#f2-cin-11-2012-001}

![3D Scatter plot of all 57 original subjects \[40 CCA (purple) and 17 NRM (green)\] used in the Discovery Study in connection with the D~1~, D~2~, and D~3~ diagnostic biomarker models.\
**Notes:** The D~1~, D~2~, and D~3~ scores of all 57 original subjects are plotted against each other (D~1~ vs. D~2~ vs. D~3~). As can be seen, there are two distinct, separate clusters: the purple one (CCA group) is at the front and at a lower level, whereas the green one (NRM group) is at the back and at a higher level. It can also be seen that there were no misclassifications.](cin-11-2012-001f3){#f3-cin-11-2012-001}

![Scatter plot and bar graph of all 39 unknown (new and different) subjects (28 CCA and 11 NRM) used in the Validation Study in connection with the D~1~ and D~2~ diagnostic biomarker models.\
**Notes:** As can be seen, 28/28 unknown CCA subjects (purple color) had D~1~ and D~2~ scores lower than the determined cut-off scores of 21.800 and 21.235, respectively; therefore, 28/28 unknown CCA subjects were identified correctly by both D~1~ and D~2~ diagnostic biomarker models \[sensitivity = 28/28 = 1.000 for both D~1~ and D~2~\]. Regarding the NRM group (green color), all 11 unknown subjects had D~1~ and D~2~ scores greater than the determined cut-off scores of 21.800 and 21.235, respectively; therefore, 11/11 unknown NRM subjects were identified correctly by both D~1~ and D~2~ diagnostic biomarker models \[specificity = 11/11 = 1.000 for both D~1~ and D~2~\]. For the Validation Study, the mean D~1~ and D~2~ scores of the 28 unknown CCA subjects were 18.5568 and 18.5869 respectively (top of the D~1~ and D~2~ purple bars) and their respective standard deviations (whiskers above or below the top of the D~1~ and D~2~ purple bars) were 1.4817 and 1.1167. The mean D~1~ and D~2~ scores of the 11 unknown NRM subjects were 23.7912 and 23.4817 respectively (top of the D~1~ and D~2~ green bars) and their respective standard deviations (whiskers above or below the top of the D~1~ and D~2~ green bars) were 0.9013 and 1.0766. The significance level was set at α = 0.001 (two-tailed), and the probability of significance for the D~1~ was *P* = 4.17 × 10^−13^ (independent *t*-Test with T-value = 10.8991), whereas the probability of significance for the D~2~ was *P* = 8.76 × 10^−15^ (independent *t*-Test with T-value = 12.4374). Both the D~1~ and the D~2~ are parametrically distributed with respect to both groups.](cin-11-2012-001f4){#f4-cin-11-2012-001}

![Scatter plot and bar graph of all 39 unknown (new and different) subjects (28 CCA and 11 NRM) used in the Validation Study in connection with the D~3~ diagnostic biomarker model.\
**Notes:** As can be seen, 28/28 unknown CCA subjects (purple color) had D~3~ scores lower than the determined cut-off score of 21.382; therefore, 28/28 unknown CCA subjects were identified correctly by the D~3~ diagnostic biomarker model \[ sensitivity = 28/28 = 1.000\]. Regarding the NRM group (green color), all 11 unknown subjects had D~3~ scores greater than the determined cut-off score of 21.382; therefore, 11/11 unknown NRM subjects were identified correctly by the D~3~ diagnostic biomarker model \[ specificity = 11/11 = 1.000\]. For the Validation Study, the mean D~3~ score of the 28 unknown CCA subjects was 18.1475 (top of the purple bar) and the standard deviation (whiskers above or below the top of the purple bar) was 1.2818. The mean D~3~ score of the 11 unknown NRM subjects was 24.5298 (top of the green bar) and the standard deviation (whiskers above or below the top of the green bar) was 1.6149. The significance level was set at α = 0.001 (two-tailed), and the probability of significance for the D~3~ was *P* = 2.30 × 10^−15^ (independent *t*-Test with T-value = 12.9987). The D~3~ is parametrically distributed with respect to both groups.](cin-11-2012-001f5){#f5-cin-11-2012-001}

![3D Scatter plot of all 39 unknown (new and different) subjects \[28 CCA (purple) and 11 NRM (green)\] used in the Validation Study in connection with the D~1~, D~2~, and D~3~ diagnostic biomarker models.\
**Notes:** The D~1~, D~2~, and D~3~ scores of all 39 unknown subjects are plotted against each other (D~1~ vs. D~2~ vs. D~3~). As can be seen, there are two distinct, separate clusters: the purple one (CCA group) is at the front and at a lower level, whereas the green one (NRM group) is at the back and at a higher level. It can also be seen that there were no misclassifications.](cin-11-2012-001f6){#f6-cin-11-2012-001}

###### 

The 12 miRNAs (constituent variables) of the three diagnostic biomarker models (D~1~, D~2~, and D~3~), ranked according to their ROC AUC value.

  Rank   ROC AUC   miRNA symbol     miRNA Signif. Diff. Expr. (CCA)   Known gene interactions                                                                                                                                                                                                                                                                                                                                                                                                Observed processes                                                                                                                                                                                                                                                                                                                                                                               Known drugs/Chemicals/Hormones
  ------ --------- ---------------- --------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1      0.99813   **miR-182\***    ↑                                                                                                                                                                                                                                                                                                                                                                                                                                                        colon cancer                                                                                                                                                                                                                                                                                                                                                                                     
  2      0.99440   **miR-182**      ↑                                 RASA1, RAC1, TP53I13, EGR3, BCL10                                                                                                                                                                                                                                                                                                                                                                                      endometrial ovarian cancer, endometrioid carcinoma, lung cancer, lung squamous cell carcinoma, metastasis, colon cancer                                                                                                                                                                                                                                                                          5-fluorouracil, vorinostat, trichostatin A, 25-hydroxy-vitamin D3, decitabine
  3      0.99360   **miR-30a-3p**   ↓                                 AQP4, CDK6, CYR61, FMR1, SLC7A6, THBS1, TMEM2, TUBA1A, VEZT, WDR82                                                                                                                                                                                                                                                                                                                                                     head and neck cancer, hypopharyngeal squamous cell carcinoma, uterine cancer, cervical carcinoma                                                                                                                                                                                                                                                                                                 vorinostat, docetaxel, Insulin
  4      0.99307   **miR-147**      ↓                                 BCL7B, TP53RK, VEGFA, PNP, FAM123C, SLC25A34, C17orf55, ONECUT2, PDLIM2, SLC8A3, HPCAL4, AHCYL1, BCOR, MAPRE3, RGS17, DGKG, SLC10A7                                                                                                                                                                                                                                                                                    hepatocellular carcinoma, liver cancer                                                                                                                                                                                                                                                                                                                                                           5-fluorouracil
  5      0.99200   **miR-183**      ↑                                 BCL10, BCL11B, BCLAF1, RBM8A, FOXO1, SRSF2, PDCD4, TRIM2, NUFIP2, GREM2, VAMP7, HECTD2, KY, PPP2R2A, CTDSPL, PLA2G2D, CDH9, THEM4, C16orf54, TUB, TUBA8, TUBGCP4                                                                                                                                                                                                                                                       liver cancer, endometrial ovarian cancer, endometrioid carcinoma, head and neck cancer, hypopharyngeal squamous cell carcinoma, hepatocellular carcinoma, melanoma metastases, melanoma, lung squamous cell carcinoma, metastasis, lung cancer                                                                                                                                                   vorinostat
  6      0.99147   **miR-378**      ↓                                 RASAL1, METTL4, RASAL1, RBBP9, RBM12, TUSC2, SUFU, SOST, TBX3, NR2C2, FAM60A, SH3GLB1, SDCCAG3, BCL2L2, TRAF5, SHANK3, CSNK1G2, SLC7A6OS, WRB, BEND4                                                                                                                                                                                                                                                                   head and neck cancer, hypopharyngeal squamous cell carcinoma                                                                                                                                                                                                                                                                                                                                     4-hydroxynonenal, 25-hydroxy-vitamin D3
  7      0.98694   HS-94            ↑                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  8      0.98507   miR-135b         ↑                                 RASAL2, RASSF2, TP53TG3/TP53TG3B, BCL11A, BCL11B, BCL2L2, BCL9L, SMAD5, APC, JAK2, ALOX5AP, SUCLG2, ZNF28, OSCP1, PDCD6IP, C1QBP, GULP1, KCTD1, YBX2, OTUD6B, BHLHB9, DEPTOR, NR3C2, RUNX2                                                                                                                                                                                                                             liver cancer, hepatocellular carcinoma, melanoma metastases, melanoma, clear-cell adenocarcinoma, renal cancer, uterine cancer, cervical carcinoma                                                                                                                                                                                                                                               perchlorate, methimazole, tretinoin
  9      0.98028   **miR-224**      ↑                                 RASA4/RASA4B, RASD1, RASEF, RASGRP1, TP53INP1, METAP2, METTL10, BCL2L11, BEND2, BEND6, API5, ZC3HC1, OSBPL11, NPY1R, ATG2B, BNIP3L, GPR137C, ZNF585A, TSPYL5, USP6NL, PLCD3, METAP2, C3orf64, ZNF140, ANKS1A, PAK4, MMP9                                                                                                                                                                                               papillary thyroid cancer, papillary thyroid carcinoma, endometrial cancer, pancreatic cancer, pancreatic ductal adenocarcinoma, lung squamous cell carcinoma, lung cancer                                                                                                                                                                                                                        docetaxel, lipopolysaccharide, fluorouracil
  10     0.97735   **miR-30a-5p**   ↓                                 RASA1, RASAL2, RASD1, RASGEF1A, RASGRP3, RASL12, RASSF4, TP53, TP53INP1, TP63, BCL10, BCL11A, BCL11B, BCL2, BCL2L11, BCL2L15, BCL6, BCL9, BCLAF1, EED, ACTBL2, ACTC1, ACTN1, NEFL, NEFM, GNAI2, NEUROD1, TMED2, TMED10, CHD1, CBFB, RAD23B, AP2A1, SLC7A11, SLC4A7, MBNL1, TNRC6A, NUFIP2, P4HA2, NT5E, BDNF, RUNX2                                                                                                    uterine cancer, liver cancer, uterine leiomyoma, papillary thyroid cancer, papillary thyroid carcinoma, head and neck cancer, hypopharyngeal squamous cell carcinoma, prostate cancer, cervical carcinoma, lung cancer, brain cancer, medulloblastoma, colorectal cancer, hepatocellular carcinoma, early-onset breast cancer, breast cancer, hormonedependent breast cancer, breast carcinoma   acetaminophen, 5-fluorouracil, docetaxel, oxaliplatin, 25-hydroxy-vitamin D3, Gulo, Hcg (chorionic gonadotropin complex), trichostatin A, ethanol, androgen, valproic acid
  11     0.97601   **miR-137**      ↓                                 RASGRP3, RASIP1, TP53TG3/TP53TG3B, TP63, BCL11A, BCL11B, BCL2L11, BCL2L13, MAF, MAFK, MED1, MED11, MED14, MED27, MEF2A, MEGF11, MEGF9, METAP1, METTL8, METTL9, ACTBL2, ACTC1, ACTN2, BCL11A, BCL11B, BCL2L11, BCL2L13, TNFAIP1, TNFAIP6, TNFAIP8, TNFSF10, TUBB1, EGR2, RB1, CDK2, CDK6, MET, MITF, CDK6, E2F6, NCOA2, SNAPC1, PLA2G15, STC2, DNAJB12, SSR1, RELL1, SLC6A17, C7orf28B/CCZ1, ASH1L, TMEM229B, C18orf1   hepatocellular carcinoma, liver cancer                                                                                                                                                                                                                                                                                                                                                           decitabine, trichostatin A, phorbol myristate acetate
  12     0.97015   miR-493--5p      ↑                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

**Note:** Their significant differential expression \[over-expression (↑) or under-expression (↓)\] as observed in the CCA group relative to the NRM group is shown, along with their symbol, known gene interactions, the processes wherein they have been observed to be involved, and known drug/chemical/hormone interactions.

###### 

Statistical results of the three diagnostic biomarker models (D~1~, D~2~, and D~3~) in the Discovery Study (identification of the 57 original subjects) and in the Validation Study (identification of the 39 unknown subjects, which were new and different from the 57 original subjects).

  Diagnostic Test            ROC AUC   T-Value   P                CCA Group                       NRM Group
  -------------------------- --------- --------- ---------------- ------------------------------- -------------------------------
  **A (Discovery study)**                                                                         
  D1                         1.000     18.4664   3.05 × 10^−25^   \[17.8457, 18.9607\] (1.0899)   \[23.2097, 24.3414\] (0.7363)
  D2                         1.000     19.3834   3.01 × 10^−26^   \[17.8040, 18.9029\] (1.0703)   \[23.3861, 24.5940\] (0.8029)
  D3                         1.000     23.1476   4.96 × 10^−30^   \[17.4960, 18.4864\] (0.9684)   \[23.7995, 25.4473\] (1.0730)
                                                                  **CCA Group**                   **NRM Group**
                                                                                                  
                                                                  **Mean ± SD**                   **Mean ± SD**
                                                                                                  
  **B (Validation study)**                                                                        
  D1                         1.000     10.8991   4.17 × 10^−13^   18.5568 ± 1.4817                23.7912 ± 0.9013
  D2                         1.000     12.4374   8.76 × 10^−15^   18.5869 ± 1.1167                23.4817 ± 1.0766
  D3                         1.000     12.9987   2.30 × 10^−15^   18.1475 ± 1.2818                24.5298 ± 1.6149

**Notes:** (**A**) The ROC AUC value, the T value and probability of significance (*P*) of the independent *t*-Test, the 99.99% confidence interval for the mean score of the CCA group and that of the NRM group, along with their respective standard deviations, of the D~1~, D~2~, and D~3~ diagnostic biomarker models in the Discovery Study are shown. (**B**) The ROC AUC value, the T value and probability of significance (P) of the independent *t*-Test, and the mean score of the CCA group and that of the NRM group, along with their respective standard deviations, of the D~1~, D~2~, and D~3~ diagnostic biomarker models in the Validation Study are shown. As can be seen, all six of those group mean scores, as observed in the validation study with the 39 unknown subjects, fall within the 99.99% confidence intervals of the respective group mean scores as predicted in the discovery study (**A**).
